Article
Chemistry, Medicinal
Philippe Bertrand
Summary: Aptamers have emerged as potential alternatives to antibodies or small molecules for targeting immune check points such as PD-1 and PD-L1. They possess high affinity for a wide range of targets including small molecules, proteins, and cells. The SELEX method is used to identify and modify aptamers for specific purposes, and their applications extend to therapy and alternative assay technologies. Strategies for managing aptamer plasma stability can be employed. This perspective provides an overview of the development of aptamers targeting immune checkpoint modulators and other immuno-related targets.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Editorial Material
Oncology
Junyun Lai, Paul A. Beavis, Jasmine Li, Phillip K. Darcy
Summary: Cancer immunotherapy has shown unprecedented clinical responses in patients with cancer, but some cancers remain refractory to these therapies. Combining adoptive T-cell therapy with checkpoint inhibition has become an innovative approach to overcome resistance in cancer treatment.
Article
Multidisciplinary Sciences
Xiaozhen Zhang, Xing Huang, Jian Xu, Enliang Li, Mengyi Lao, Tianyu Tang, Gang Zhang, Chengxiang Guo, Xiaoyu Zhang, Wen Chen, Dipesh Kumar Yadav, Xueli Bai, Tingbo Liang
Summary: The study reveals that NEK2 phosphorylates PD-L1 to maintain stability, impacting the efficacy of immunotherapy in pancreatic cancer, while NEK2 deficiency enhances lymphocyte infiltration and sensitivity to immunotherapy. Inhibiting NEK2 can enhance PD-L1 blockade, potentially improving the effectiveness of pancreatic cancer treatment.
NATURE COMMUNICATIONS
(2021)
Review
Medicine, Research & Experimental
Elina Khatoon, Dey Parama, Aviral Kumar, Mohammed S. Alqahtani, Mohamed Abbas, Sosmitha Girisa, Gautam Sethi, Ajaikumar B. Kunnumakkara
Summary: Ovarian cancer is a deadly gynecological cancer with a low survival rate. Recent advancements in immunotherapy, particularly targeting the PD-1/PD-L1 axis, have shown promise in enhancing anti-tumor activity. Combinatorial treatment with small molecule inhibitors has also shown improved efficacy.
Article
Chemistry, Medicinal
Tianyu Wang, Shi Cai, Yao Cheng, Wanheng Zhang, Minmin Wang, Huiyong Sun, Binghua Guo, Zheng Li, Yibei Xiao, Sheng Jiang
Summary: Compound 17 is a bifunctional inhibitor that can block the interactions between PD-1 and PD-L1, promoting internalization and degradation of PD-L1. It effectively suppresses tumor growth in vivo by activating antitumor immunity.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Materials Science, Multidisciplinary
Tao Huang, Xianfu Sun, Xiaocao Meng, Mengdie Chen, Yapeng Li, Shengnan Du, Yingqiu Qi, Hong Ge
Summary: The amphiphilic peptide based on D-peptide can self-assemble into stable nanostructures, inhibit tumor growth effectively, and activate the immune response. The prepared CD-NPs show significant therapeutic effects on tumors and demonstrate good biocompatibility.
FRONTIERS IN MATERIALS
(2022)
Article
Medicine, Research & Experimental
Po-Lin Huang, Hung-Tsai Kan, Ching-Hsuan Hsu, Hsin-Ta Hsieh, Wan-Chien Cheng, Ren-Yeong Huang, Jhong-Jhe You
Summary: The bispecific antibody AP203, targeting PD-L1 and CD137, demonstrates potent antitumor activity by blocking inhibitory signaling and activating costimulatory signaling in effector T cells. This leads to enhanced T cell activation, memory recall responses, and a reduction in Treg-mediated immunosuppression. The preclinical results suggest that AP203 is a promising candidate for clinical treatment of solid tumors.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Review
Immunology
Youliang Zhao, Yaqian Qu, Changfu Hao, Wu Yao
Summary: Fibrosis is a pathological process characterized by excessive accumulation of extracellular matrix, leading to permanent scarring and organ failure. The immune system, particularly the immune checkpoint molecule PD-1/PD-L1 axis, plays a crucial role in the initiation and progression of fibrosis. The therapeutic targeting of PD-1/PD-L1 axis for tumor immunotherapy has provided new insights for its potential use in fibrotic diseases. This review discusses the structure, function, and regulatory mechanism of PD-1 and PD-L1, and summarizes the research progress of PD-1/PD-L1 signaling in fibrotic diseases.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Fei Zhou, Xiaojiaoyang Li, Kexin Jia, Fanghong Li, Xiaoyong Xue, Jia Liu, Jiaorong Qu, Runping Liu
Summary: This study utilized a novel autophagy inhibitor tetramethylpyrazine (TMP) to enhance the recruitment of immune cells into tumors, thus boosting antitumor immune responses. A liposomal system co-delivering DOX and TMP was developed and modified with a PD-L1 binding peptide, showing potent anti-tumor efficacy in vitro by inhibiting autophagy flux and upregulating chemokines. The findings suggest a promising natural product-based nanomedicine for cancer immunotherapy.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Lin Zhao, Xi Chen, Honghai Wu, Qiaojun He, Ling Ding, Bo Yang
Summary: Anti-PD-1/PD-L1 antibodies have limited efficacy in ovarian cancer due to impaired cancer-immunity cycle and tumor immune microenvironment. Combinatorial strategies to modify the cycle and remodel the microenvironment are of great importance.
BIOCHEMICAL PHARMACOLOGY
(2023)
Review
Multidisciplinary Sciences
Tuan Hiep Tran, Thi Thu Phuong Tran
Summary: Nanomedicine has potential in oncology field, but only a few products have been approved. Immunotherapy, as a new direction in cancer treatment, still requires further development. Using PD-1/PD-L1-targeting nanocarriers can enhance treatment outcomes.
ROYAL SOCIETY OPEN SCIENCE
(2022)
Article
Biochemistry & Molecular Biology
Qian Wu, Yingjie Xu, Xujun Li, Huina Liu, Tianzi You, Ting Cai, Fan Yang
Summary: This study found that PD-1 is aberrantly upregulated in TNBC patients and cell lines. Cell-intrinsic PD-1 in TNBC cells significantly facilitated tumor growth and metastasis through the cell-intrinsic PD-1/PD-L1 pathway, which is regulated by the gene expression regulator YB-1. Silencing YB-1 expression in TNBC cells inhibits cell proliferation, tumorigenesis, and metastasis, and this inhibition can be rescued by simultaneous exogenous expression of PD-1 and PD-L1 proteins.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
(2022)
Article
Engineering, Biomedical
Yunjian Yu, Jie Li, Boyi Song, Zhuang Ma, Yufei Zhang, Haonan Sun, Xiaosong Wei, Yayun Bai, Xueguang Lu, Peng Zhang, Xinge Zhang
Summary: An all synthetic nanoparticle with PD-L1 blockade capability is developed for cancer photothermal-immunotherapy, offering a simple but promising approach for the treatment of metastatic cancer.
Article
Biochemistry & Molecular Biology
Nadia Mensali, Pierre Dillard, Artem Fayzullin, Hakan Koksal, Gustav Gaudernack, Gunnar Kvalheim, Else Marit Inderberg, Sebastien Walchli
Summary: The success of adoptive cell therapy relies on the ability of immune cells to persist and function optimally in the tumor microenvironment. Novel genetic strategies to manipulate the PD1/PD-L1 axis can improve antitumor immunity and reveal new targets through PD-L1 positivity.
Article
Chemistry, Multidisciplinary
Zikuan Gu, Shuxin Xu, Zhanchen Guo, Zhen Liu
Summary: This study presents a molecularly imprinted polymer-based PD-1 nano inhibitor, which effectively blocks the PD-1/PD-L1 signaling pathway with good specificity and high affinity. The inhibitor can reactivate T cells and reverse the chemoresistance of tumor cells, providing a promising option for cancer immunotherapy.
Article
Oncology
Qi Cao, Zhengshuai Song, Hailong Ruan, Cheng Wang, Xiong Yang, Lin Bao, Keshan Wang, Gong Cheng, TianBo Xu, Wen Xiao, Zhiyong Xiong, Di Liu, Ming Yang, Diwei Zhou, Hongmei Yang, Ke Chen, Xiaoping Zhang
CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
Rumeng Yang, Zitian Huo, Yaqi Duan, Weilin Tong, Yiyun Zheng, Yinxia Su, Liping Lou, Qian Zhang, Sanpeng Xu, Changqing Peng, Dong Kuang, Guoping Wang
LEUKEMIA & LYMPHOMA
(2020)
Article
Medicine, General & Internal
Tongjuan Li, Jiaqi Tan, Liting Chen, Dong Kuang, Xia Mao, Yaoyao Lou, Jianfeng Zhou, Xiaoxi Zhou
Article
Biotechnology & Applied Microbiology
Junyi Hu, Zhaohui Chen, Lin Bao, Lijie Zhou, Yaxin Hou, Lilong Liu, Ming Xiong, Yuhan Zhang, Bin Wang, Zhen Tao, Ke Chen
Article
Oncology
Yixin Cai, Zhipeng Hao, Yi Gao, Wei Ping, Qi Wang, Shu Peng, Bo Zhao, Wei Sun, Min Zhu, Kaiyan Li, Ying Han, Dong Kuang, Qian Chu, Xiangning Fu, Ni Zhang
JOURNAL OF THORACIC ONCOLOGY
(2020)
Article
Oncology
Bin Wang, Lin Sun, Zhiyong Yuan, Zhen Tao
Article
Multidisciplinary Sciences
Zhaohui Chen, Lijie Zhou, Lilong Liu, Yaxin Hou, Ming Xiong, Yu Yang, Junyi Hu, Ke Chen
NATURE COMMUNICATIONS
(2020)
Article
Oncology
Ke Chen, Xuanmao Jiao, Anthony Ashton, Agnese Di Rocco, Timothy G. Pestell, Yunguang Sun, Jun Zhao, Mathew C. Casimiro, Zhiping Li, Michael P. Lisanti, Peter A. McCue, Duanwen Shen, Samuel Achilefu, Hallgeir Rui, Richard G. Pestell
Article
Oncology
Hailong Ruan, Lin Bao, Zhen Tao, Ke Chen
Summary: This study found that downregulation of FLII can lead to immune evasion in prostate cancer during the emergence of endocrine therapy resistance, which is achieved through activation of the YBX1/PD-L1 signaling pathway. Additionally, restoration of FLII expression reversed enzalutamide resistance, activating T-cell responses by inhibiting the YBX1/PD-L1 pathway.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Oncology
Lijie Zhou, Cai Zhang, Xiong Yang, Lilong Liu, Junyi Hu, Yaxin Hou, Hong Tao, Haruhiko Sugimura, Zhaohui Chen, Liang Wang, Ke Chen
Summary: The study found that MLT has an inhibitory effect on tumor growth and can reverse resistance in CRPC models by restoring CES1 expression and reducing lipid droplet accumulation. Mechanistic investigations showed that MLT regulates CES1's epigenetic modifications to suppress PCa development.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Bin Wang, Yang Dong, Xuyao Yu, Fengtong Li, Jingsheng Wang, Huaming Chen, Zeqian Niu, Yongchun Song, Zhiyong Yuan, Zhen Tao
Summary: SBRT treatment at a dose of 56 Gy/6-8f is beneficial for UCLC patients, and smaller PTV is associated with better outcomes.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Lilong Liu, Yaxin Hou, Changqi Deng, Zhen Tao, Zhaohui Chen, Junyi Hu, Ke Chen
Summary: This study identifies CD39 as a potential therapeutic target for bladder cancer through single-cell RNA sequencing and validates its inhibitory effect on tumor growth and improvement of overall survival in vivo. The findings confirm the potential importance of CD39 as an immune therapy target for bladder cancer.
NATURE COMMUNICATIONS
(2022)